MedTrace Logo

Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate

NCT00349739 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2010-01-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether anecortave acetate can slow or stop the progression of age-related macular degeneration in patients who do not qualify for other studies and have no other treatment options.

Conditions

  • Macular Degeneration

Interventions

DRUG

Anecortave Acetate

Dosage: 0.5ml of 30mg/ml(15 mg) or 60mg/ml(30mg) Duration of action: 159-180 days

Sponsors & Collaborators

  • University of Iowa

    lead OTHER

Principal Investigators

  • Edwin M Stone, MD, PhD · University of Iowa

  • Stephen R. Russell, MD · University of Iowa

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00349739 on ClinicalTrials.gov